 |
| |
| Jan-31-20 | Upgrade |
JP Morgan |
Neutral → Overweight |
$120 |
|
| Dec-03-19 | Initiated |
BofA/Merrill |
Underperform |
|
|
| Aug-01-19 | Upgrade |
Ladenburg Thalmann |
Neutral → Buy |
$103 → $106 |
|
| Aug-01-19 | Upgrade |
Jefferies |
Underperform → Hold |
$90 |
|
| Jul-01-19 | Upgrade |
Credit Suisse |
Neutral → Outperform |
$98 → $101 |
|
| May-17-19 | Upgrade |
UBS |
Sell → Neutral |
$115 → $94 |
|
| May-09-19 | Upgrade |
Credit Suisse |
Underperform → Neutral |
$98 |
|
| Oct-12-18 | Upgrade |
Standpoint Research |
Hold → Buy |
|
|
| Aug-08-18 | Downgrade |
Credit Suisse |
Neutral → Underperform |
|
|
| Apr-03-18 | Upgrade |
Credit Suisse |
Underperform → Neutral |
|
|
| Feb-22-18 | Reiterated |
Barclays |
Underweight |
$115 → $105 |
|
| Jan-18-18 | Resumed |
Credit Suisse |
Underperform |
$118 |
|
| Dec-27-17 | Reiterated |
Wedbush |
Outperform |
$213 → $232 |
|
| Apr-27-17 | Reiterated |
Wedbush |
Outperform |
$229 → $213 |
|
| Mar-30-17 | Initiated |
UBS |
Sell |
$112 |
|
| Mar-16-17 | Initiated |
Credit Suisse |
Underperform |
|
|
| Mar-06-17 | Downgrade |
Jefferies |
Hold → Underperform |
|
|
| Feb-23-17 | Downgrade |
Ladenburg Thalmann |
Buy → Neutral |
|
|
| Jan-19-17 | Downgrade |
Standpoint Research |
Buy → Hold |
|
|
| Dec-15-16 | Initiated |
Oppenheimer |
Outperform |
|
|
|
|
| Feb-21-20 02:25PM | Corcept (CORT) Q4 Earnings In-Line with Estimates, Up Y/Y Zacks |
| Feb-19-20 12:31PM | Earnings Preview: United Therapeutics (UTHR) Q4 Earnings Expected to Decline Zacks |
| 11:13AM | Zacks.com featured highlights include: Tempur Sealy International, Twin River Worldwide, Rite Aid, DaVita and United Therapeutics Zacks |
| 06:00AM | United Therapeutics Corporation to Report Fourth Quarter and Full Year 2019 Financial Results Before the Market Opens on Wednesday, February 26, 2020 PR Newswire |
| Feb-18-20 09:51AM | 5 Stocks in Focus on Remarkable Relative Price Strength Zacks |
| Feb-14-20 10:36AM | New Strong Buy Stocks for February 14th Zacks |
| Feb-05-20 03:01PM | Court sides with United Therapeutics in suit from generic competitor, but doesn't dismiss case American City Business Journals |
| 02:39PM | 5 Stocks Trading Below Peter Lynch Value GuruFocus.com |
| 11:15AM | Biotech Stock Roundup: Earnings Updates From VRTX, AMGN, GILD; AIMT Gains FDA Nod Zacks |
| 07:43AM | The Daily Biotech Pulse: Merck Spins Off Slow-Growth Businesses, ZioPharm Announces Offering, PhaseBio Data Benzinga |
| Feb-04-20 12:10PM | Why United Therapeutics (UTHR) is Poised to Beat Earnings Estimates Again Zacks |
| Feb-03-20 08:42AM | United Therapeutics gets disappointing news on cancer therapy American City Business Journals |
| 06:00AM | United Therapeutics Announces Study of Unituxin® (dinutuximab) for Small Cell Lung Cancer Did Not Meet Primary Endpoint PR Newswire |
| Jan-17-20 08:16AM | Arena's (ARNA) Heart Failure Candidate Gets Fast Track Status Zacks |
| Jan-06-20 06:00AM | United Therapeutics Corporation To Present At The 38th Annual J.P. Morgan Healthcare Conference PR Newswire |
| Jan-03-20 09:01AM | Arena (ARNA) Expands Strategic Deal With Beacon Discovery Zacks |
| Dec-27-19 03:40PM | Hedge Fund Favorites vs. United Therapeutics Corporation (UTHR) In 2019 Insider Monkey |
| Dec-17-19 02:07PM | Are Investors Undervaluing United Therapeutics Corporation (NASDAQ:UTHR) By 41%? Simply Wall St. |
| Dec-06-19 03:07PM | Brandes Investments' Top 5 Buys in the 3rd Quarter GuruFocus.com |
| Dec-03-19 04:44PM | United Therapeutics (UTHR): Hedge Funds Were Patiently Waiting For Strong Gains Insider Monkey |
| 02:43PM | Bank Of America Initiates United Therapeutics With Bearing Rating, Cites Unclear Growth Outlook Benzinga |
| Nov-14-19 07:00AM | Correvio Reports Third Quarter 2019 Financial Results CNW Group |
| Nov-08-19 08:56AM | Arena Pharmaceuticals' (ARNA) Q3 Loss Widens, Revenues Beat Zacks |
| Nov-04-19 11:38AM | Edited Transcript of UTHR earnings conference call or presentation 30-Oct-19 1:00pm GMT Thomson Reuters StreetEvents |
| Oct-31-19 11:45AM | United Therapeutics (UTHR) Q3 Earnings & Sales Top, Stock Up Zacks |
| 06:50AM | Will United Therapeutics Continue to Surge Higher? Zacks |
| Oct-30-19 10:54AM | Zacks.com featured highlights include: Plexus, Costamare, United Therapeutics, Intel and First American Financial Zacks |
| 07:30AM | United Therapeutics (UTHR) Tops Q3 Earnings and Revenue Estimates Zacks |
| 06:00AM | United Therapeutics Corporation Reports Third Quarter 2019 Financial Results PR Newswire |
| Oct-29-19 10:40AM | Exelixis (EXEL) to Report Q3 Earnings: What's in the Cards? Zacks |
| 10:10AM | Will United Therapeutics (UTHR) Beat Estimates Again in Its Next Earnings Report? Zacks |
| 08:44AM | 5 Solid Relative Price Strength Stocks to Make You Rich Zacks |
| Oct-25-19 11:28AM | United Therapeutics Corporation (UTHR): Hedge Funds Had A Change of Heart Insider Monkey |
| Oct-23-19 10:33AM | Analysts Estimate United Therapeutics (UTHR) to Report a Decline in Earnings: What to Look Out for Zacks |
| 06:00AM | United Therapeutics Corporation to Report Third Quarter 2019 Financial Results Before the Market Opens on Wednesday, October 30, 2019 PR Newswire |
| Oct-21-19 06:00AM | United Therapeutics Announces FDA Approval Of Updated Label For Orenitram Reflecting Results Of FREEDOM-EV Study PR Newswire |
| Oct-18-19 11:12AM | Does United Therapeutics Corporation (NASDAQ:UTHR) Have A Volatile Share Price? Simply Wall St. |
| Oct-14-19 09:15AM | Zoetis (ZTS) Soars to 52-Week High, Time to Cash Out? Zacks |
| Oct-02-19 05:00AM | Some local CEOs are paid much more than their employees here's how much American City Business Journals |
| Sep-18-19 05:58AM | Investors Who Bought United Therapeutics (NASDAQ:UTHR) Shares Five Years Ago Are Now Down 38% Simply Wall St. |
| Sep-12-19 11:25AM | United Therapeutics' Trevyent NDA for PAH Accepted by FDA Zacks |
| 07:00AM | Correvio Highlights FDA Acceptance of United Therapeutics' Trevyent New Drug Application CNW Group |
| Sep-11-19 06:00AM | United Therapeutics Announces FDA Acceptance Of Trevyent New Drug Application For Review PR Newswire |
| Aug-23-19 12:00PM | MNKD: Q2 2019: Record Revenue, Margins as Rx Continue to Ramp. Clinical Evidence Driving Adoption Zacks Small Cap Research |
| Aug-19-19 04:35PM | iBio Inks 3D Bioprinting Agreement GlobeNewswire |
| Aug-16-19 09:24AM | Is United Therapeutics Corporation's (NASDAQ:UTHR) CEO Paid Enough Relative To Peers? Simply Wall St. |
| Aug-14-19 07:00AM | Correvio Reports Second Quarter 2019 Financial Results CNW Group |
| Aug-10-19 08:32AM | Edited Transcript of UTHR earnings conference call or presentation 31-Jul-19 1:00pm GMT Thomson Reuters StreetEvents |
| Aug-09-19 09:25AM | Zoetis (ZTS) Hits Fresh High: Is There Still Room to Run? Zacks |
| Aug-08-19 11:23AM | MannKind Corporation (MNKD) Q2 2019 Earnings Call Transcript Motley Fool |
| 10:34AM | Arena Pharmaceuticals' (ARNA) Q2 Loss Widens, Revenues Meet Zacks |
| Aug-06-19 06:00AM | United Therapeutics Corporation To Present At 2019 Wedbush PacGrow Healthcare Conference PR Newswire |
| Aug-01-19 09:49AM | United Therapeutics (UTHR) Q2 Earnings & Sales Beat, Down Y/Y Zacks |
| Jul-31-19 11:01PM | United Therapeutics Corporation (UTHR) 2019 Q2 Earnings Call Transcript Motley Fool |
| 02:44PM | United Therapeutics is executing its growth plan. Why isnt its stock price higher? American City Business Journals |
| 07:30AM | United Therapeutics (UTHR) Q2 Earnings and Revenues Beat Estimates Zacks |
| 06:00AM | United Therapeutics Corporation Reports Second Quarter 2019 Financial Results PR Newswire |
| Jul-24-19 06:00AM | United Therapeutics Corporation To Report Second Quarter 2019 Financial Results Before The Market Opens On Wednesday, July 31, 2019 PR Newswire |
| Jul-17-19 01:00PM | What You Should Know About United Therapeutics Corporation's (NASDAQ:UTHR) Financial Strength Simply Wall St. |
| Jul-11-19 12:25AM | Sexual harassment lawsuit against Md. biotech to advance with plaintiff's identity revealed American City Business Journals |
| Jul-03-19 09:15AM | S&P Makes It Two Record Closes in a Row Zacks |
| Jul-01-19 02:37PM | Credit Suisse: United Therapeutics Becoming More Fundamentally Driven Benzinga +5.11% |
| 09:28AM | United Therapeutics Stock Jumps After Analyst Says Its Slide Was Overdone Barrons.com |
| Jun-26-19 09:15AM | Stocks Slide as Fed Dampens Rate Cut Expectations Zacks |
| Jun-18-19 10:38AM | Arena Initiates Dosing in Pivotal Colitis Study on Etrasimod Zacks |
| Jun-17-19 02:59PM | Have Insiders Been Selling United Therapeutics Corporation (NASDAQ:UTHR) Shares? Simply Wall St. |
| Jun-13-19 11:19AM | Heres What Hedge Funds Think About United Therapeutics Corporation (UTHR) Insider Monkey |
| Jun-10-19 01:01PM | Impact on Jacksonville of mega-merger of United Technologies and Raytheon is uncertain American City Business Journals |
| Jun-05-19 06:00AM | United Therapeutics Corporation to Present at Goldman Sachs 40th Annual Global Healthcare Conference PR Newswire |
| May-28-19 06:00AM | United Therapeutics Corporation To Present at Jefferies 2019 Healthcare Conference PR Newswire |
| May-23-19 11:42AM | The Catalyst: Creating Innovation in Health Care - United Therapeutics' Martine Rothblatt at Healthy Returns CNBC Videos |
| May-09-19 09:03AM | Arena Pharmaceuticals' (ARNA) Loss Widens in Q1 But Stock Up Zacks |
| May-08-19 03:50PM | Before You Buy United Therapeutics Corporation (NASDAQ:UTHR), Consider Its Volatility Simply Wall St. |
| 09:24AM | MannKind Corporation (MNKD) Q1 2019 Earnings Call Transcript Motley Fool |
| May-07-19 03:27PM | Edited Transcript of UTHR earnings conference call or presentation 1-May-19 1:00pm GMT Thomson Reuters StreetEvents |
| 06:00AM | United Therapeutics And DEKA Announce FDA Clearance Of The Unity Subcutaneous Delivery System For Remodulin® PR Newswire |
| May-02-19 05:25PM | United Therapeutics zeroes in on new business lines in wake of generic competition American City Business Journals |
| 09:26AM | United Therapeutics (UTHR) Down Despite Q1 Earnings Beat Zacks |
| May-01-19 01:16PM | United Therapeutics (UTHR) Beats Q1 Earnings and Revenue Estimates Zacks |
| 12:45PM | United Therapeutics Corporation (UTHR) Q1 2019 Earnings Call Transcript Motley Fool |
| 06:16AM | United Therapeutics: 1Q Earnings Snapshot Associated Press |
| 06:00AM | United Therapeutics Corporation Reports First Quarter 2019 Financial Results PR Newswire |
| Apr-29-19 06:00AM | United Therapeutics Announces FDA Approval Of XPS And Steen Solution Used To Perform Centralized Ex-Vivo Lung Perfusion Services PR Newswire |
| Apr-24-19 10:33AM | United Therapeutics (UTHR) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Zacks |
| 06:00AM | United Therapeutics Corporation To Report First Quarter 2019 Financial Results Before The Market Opens On Wednesday, May 1, 2019 PR Newswire |
| Apr-23-19 09:09PM | Is United Therapeutics Corporation (UTHR) A Good Stock To Buy? Insider Monkey +5.53% |
| Apr-17-19 10:52PM | United Therapeutics Issues Statement In Response To Meritless Lawsuit PR Newswire -5.93% |
| Apr-12-19 01:16PM | Is United Therapeutics Corporation's (NASDAQ:UTHR) Liquidity Good Enough? Simply Wall St. |
| Apr-10-19 09:20AM | Biotech Stock Roundup: AMGN's Evenity Earns FDA Approval, Deal Wins & More Zacks |
| Apr-09-19 10:06AM | United Therapeutics Discontinues PAH Drug After Study Fails Zacks |
| 09:30AM | Company News For Apr 9, 2019 Zacks |
| Apr-08-19 02:52PM | United Therapeutics drops drug prospect after failed trial American City Business Journals -5.70% |
| 12:48PM | Stocks making the biggest moves midday: Snap, GE, Boeing, AMC & more CNBC |
| 06:00AM | United Therapeutics Announces BEAT Study of Esuberaprost Does Not Meet Primary Endpoint PR Newswire |
| Apr-01-19 08:00AM | Report: Exploring Fundamental Drivers Behind Coeur Mining, Owens & Minor, Telenav, Cedar Realty Trust, j2 Global, and United Therapeutics New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire |
| Mar-29-19 09:30AM | United Therapeutics (UTHR) Down 7.2% Since Last Earnings Report: Can It Rebound? Zacks |
| Mar-28-19 03:10PM | Supernus reports mixed ADHD drug trial results. So why isn't it worried? American City Business Journals |
| Mar-12-19 06:00AM | United Therapeutics Corporation to Present at Oppenheimer 29th Annual Healthcare Conference PR Newswire |
| Mar-11-19 12:48PM | Update: United Therapeutics (NASDAQ:UTHR) Stock Gained 16% In The Last Five Years Simply Wall St. |
| Mar-05-19 10:55AM | MNKD: A Head Start to 2019; Q4 and Annual 2018 Earnings Results Zacks Small Cap Research |
|
|
|
|
| United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma. It also engages in developing esuberaprost, RemoPro, Treprostinil Technosphere, Trevyent, ralinepag, and Aurora-GT to treat PAH; and the research and development of various organ transplantation-related technologies, including regenerative medicine, xenotransplantation, biomechanical lungs, and ex-vivo lung perfusion, as well as the development of medicine for other diseases. United Therapeutics Corporation has licensing and collaboration agreements with Medtronic, Inc. to develop and commercialize the implantable system for Remodulin in the United States, the United Kingdom, Canada, France, Germany, Italy, and Japan; DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of Remodulin; MannKind Corporation to develop and license treprostinil inhalation powder, and Dreamboat and Cricket devices; Arena Pharmaceuticals, Inc. to develop ralinepag for the treatment of PAH; and Samumed LLC to develop SM04646, a phase I development-stage Wnt pathway inhibitor for treating idiopathic pulmonary fibrosis. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Mesa Nilda | Director | Oct 31 | Option Exercise | 0.00 | 2,660 | 0 | 2,660 | Jan 16 04:06 PM | | DWEK RAYMOND | Director | Jun 27 | Sale | 76.11 | 3,750 | 285,413 | 0 | Jun 28 04:25 PM | | DWEK RAYMOND | Director | Jun 26 | Option Exercise | 0.00 | 3,750 | 0 | 3,750 | Jun 28 04:25 PM | | Thompson Tommy G | Director | Jun 26 | Option Exercise | 0.00 | 1,870 | 0 | 21,940 | Jun 28 04:24 PM | | KURZWEIL RAY | Director | Jun 26 | Option Exercise | 0.00 | 1,870 | 0 | 5,240 | Jun 28 04:18 PM | | Olian Judy D. | Director | Jun 26 | Option Exercise | 0.00 | 1,870 | 0 | 8,000 | Jun 28 04:20 PM | | Giltner Richard | Director | Jun 26 | Option Exercise | 0.00 | 3,750 | 0 | 3,750 | Jun 28 04:15 PM | | SULLIVAN LOUIS W | Director | Jun 26 | Option Exercise | 0.00 | 3,750 | 0 | 5,120 | Jun 28 04:13 PM | | Giltner Richard | Director | Jun 20 | Option Exercise | 41.14 | 5,000 | 205,700 | 5,000 | Jun 21 09:03 AM | | Giltner Richard | Director | Jun 20 | Sale | 79.05 | 5,000 | 395,250 | 0 | Jun 21 09:03 AM | | Giltner Richard | Director | Jun 13 | Option Exercise | 41.14 | 5,000 | 205,700 | 5,000 | Jun 13 04:04 PM | | Giltner Richard | Director | Jun 06 | Option Exercise | 41.14 | 5,000 | 205,700 | 5,000 | Jun 06 04:01 PM | | Giltner Richard | Director | May 30 | Option Exercise | 41.14 | 5,000 | 205,700 | 5,000 | May 31 04:07 PM | | Giltner Richard | Director | Apr 05 | Option Exercise | 41.14 | 5,000 | 205,700 | 5,000 | Apr 05 04:10 PM | | CAUSEY CHRISTOPHER | Director | Apr 04 | Option Exercise | 63.90 | 750 | 47,925 | 1,725 | Apr 05 04:11 PM | | MAHON PAUL A | EVP & General Counsel | Mar 21 | Option Exercise | 92.53 | 6,000 | 555,180 | 41,323 | Mar 22 04:11 PM | | PATUSKY CHRISTOPHER | Director | Mar 20 | Option Exercise | 54.77 | 5,000 | 273,850 | 5,000 | Mar 22 04:16 PM | | ROTHBLATT MARTINE A | Chairman & CEO | Mar 19 | Option Exercise | 52.65 | 7,055 | 371,446 | 7,195 | Mar 20 04:03 PM | | Thompson Tommy G | Director | Mar 18 | Option Exercise | 52.65 | 17,100 | 900,315 | 20,070 | Mar 19 05:35 PM | | ROTHBLATT MARTINE A | Chairman & CEO | Mar 18 | Option Exercise | 52.65 | 7,055 | 371,446 | 7,195 | Mar 20 04:03 PM | | CAUSEY CHRISTOPHER | Director | Mar 14 | Option Exercise | 63.90 | 750 | 47,925 | 1,725 | Mar 18 08:03 AM | | MAHON PAUL A | EVP & General Counsel | Mar 07 | Option Exercise | 65.80 | 6,000 | 394,800 | 41,823 | Mar 08 04:01 PM | | PATUSKY CHRISTOPHER | Director | Mar 07 | Sale | 110.75 | 3,370 | 373,228 | 0 | Mar 08 04:02 PM | | SULLIVAN LOUIS W | Director | Mar 01 | Option Exercise | 54.77 | 1,000 | 54,770 | 2,370 | Mar 04 05:25 PM |
|
|
|
|
|
|
